Your senator has roughly 30 staffers covering every issue from agriculture to defense. The pharmaceutical industry has hundreds of lobbyists working Washington full time. That asymmetry shows up in your pharmacy bill, three to ten times higher than peer countries.
A lobbyist is a professional hired to influence government policy on behalf of a paying client. Corporations, trade associations, foreign governments, and advocacy groups all hire lobbyists to shape legislation, regulation, and government spending in their favor. In 2024, clients spent more than $4 billion on federal lobbying in the United States. That money pays for access to the people writing the laws that govern your drug prices, your rent, your wages, and your workplace.
Lobbying is legal. Lobbyists register with the federal government, disclose their clients, and file reports on their activity. The industry operates in the open. It's large, it's organized, and it shapes policy outcomes in ways that consistently favor the industries paying for it over the ordinary Americans affected by it.
The public image of a lobbyist is someone buttonholing a politician in a hallway. The reality is more systematic and more effective than that.
Registered lobbyists spend their days meeting with congressional staff, attending committee hearings, submitting written testimony, drafting legislative language, and building relationships with the people who make decisions. They provide research, data, and technical expertise that congressional offices often lack the staff to develop on their own. When a committee is drafting a bill that affects a particular industry, lobbyists for that industry are frequently in the room, or at least in regular contact with the staff who are.
They also monitor everything. A lobbyist representing a pharmaceutical company tracks every bill, every amendment, every committee hearing, and every regulatory proceeding that could affect drug pricing or patent protections. When something moves that their client doesn't like, they move to stop it or reshape it. When something moves that their client wants, they push to accelerate it. They do this full time, with significant resources, on behalf of clients whose profits depend on the outcomes.
Your senator has a staff of roughly thirty people covering every issue from agriculture to defense to healthcare. The pharmaceutical industry has hundreds of lobbyists working Washington full time. The asymmetry in attention and resources is not close, and it shows in the results.
The most valuable thing a lobbyist can offer a client is relationships. Former members of Congress, former senior congressional staff, and former executive branch officials carry those relationships out of government and into lobbying firms, where they become billable assets.
A senator who spent twelve years on the Finance Committee overseeing tax policy leaves office and joins a lobbying firm. Her former colleagues take her calls. Her former staff, now running the committee, know her. She understands the process from the inside, knows which members can be moved and which can't, and knows how to get language into a bill during markup. Her clients pay for all of that.
The flow runs in both directions. Lobbyists move into government positions where they regulate the industries they previously represented, then move back out again. A pharmaceutical industry lobbyist takes a senior position at the FDA, oversees drug approvals and pricing policy for a few years, then returns to the private sector with new relationships and new expertise. The industries that produce the most revolving door traffic, finance, pharmaceuticals, defense, and energy, are the same industries that get the most favorable regulatory treatment.
Every dollar spent on lobbying is an investment with an expected return. The pharmaceutical industry spent heavily for decades to prevent Medicare from negotiating drug prices. That investment paid off in protected pricing power worth hundreds of billions of dollars. The cost shows up in your pharmacy bills, which are three to ten times higher in the United States than in comparable countries.
The real estate and construction lobby spends to block zoning reform and tenant protections. The return is a housing market where supply stays artificially constrained and rents rise faster than wages. The financial industry lobbies to weaken regulations on the practices that generate their highest profits. The return is a financial system that periodically blows up and gets bailed out while ordinary Americans absorb the losses.
The $4 billion spent on federal lobbying in 2024 produced returns measured in the trillions across the industries doing the spending. From their perspective, it's among the most rational investments they make. From your perspective, it's a system that takes money out of your paycheck, your rent payment, and your pharmacy bill and routes it to shareholders and executives.
Labor Party candidates don't take corporate money, which means the industries that fund lobbying operations have less reason to invest in the relationships that produce access. A politician who has never taken pharmaceutical donations and never will has a different relationship with the pharmaceutical lobby than one whose campaigns they've funded for twenty years.
The lobbyists remain. The industry keeps spending. What changes is who they're spending on and who they can reach. A legislature full of Labor Party members would be a legislature where the pharmaceutical industry's calls get returned less reliably, where the real estate lobby's technical input carries less weight in markup sessions, and where the financial industry's preferred language is less likely to end up in the final bill.
It's the first step toward a complete solution: electing people who don't owe the lobbyists anything.
.png){kind=small}
_logo.svg.png){kind=logo}
